Treatment of estrogen-induced dermatitis with omalizumab

If you need an accessible version of this item, please email your request to digschol@iu.edu so that they may create one and provide it to you.
Date
2019-05-25
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Elsevier
Abstract

In 1945, Drs Bernhard Zondek and Yehuda Bromberg demonstrated intradermal treatment with estrone and estradiol benzoate induced urticarial lesions in some patients.1 Fifty years later, Shelley et al,2 who introduced the concept of progesterone dermatitis several decades prior, defined estrogen dermatitis based on studies of 7 women with premenstrual flares of skin eruptions including papulovesicular, urticarial, or eczematous lesions or generalized pruritus. Previously described therapies for estrogen dermatitis include estrogen desensitization, tamoxifen, leuprolide, and oophorectomy.3 Here we report a case of estrogen-induced dermatitis successfully treated with omalizumab.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Ocana, J. A., Bell, M. C., Heskett, J. B., Baker, W. H., Mousdicas, N., & Turner, M. J. (2019). Treatment of estrogen-induced dermatitis with omalizumab. JAAD case reports, 5(6), 481–483. doi:10.1016/j.jdcr.2019.03.007
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
JAAD Case Reports
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Full Text Available at
This item is under embargo {{howLong}}